Walter Martinez
Neurology with Special Qualifications in Child Neurology · West Palm Beach, FLNPI 1194827329
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,356 and has fallen 94.5% since, to $75 in 2023. That places this record below the midpoint for neurology with special qualifications in child neurology clinicians in FL, where the typical reported total is $2,700.
Across 189 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$489
- UCB, Inc.$386
- Sanofi$386
- Lundbeck LLC$295
- AbbVie$231
- Almatica Pharma LLC$201
- plus $1K from 32 others
Across 126 payments — averaging $14,974 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$912K
- Genentech, Inc.$550K
- Janssen Research & Development, LLC$250K
- Eisai Inc.$83K
- Eli Lilly$79K
- Avanir Pharmaceuticals, Inc.$12K
What the payments were for
- Food & beverage$3,467100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 35 | $489 |
| UCB, Inc. | 18 | $386 |
| Sanofi | 15 | $386 |
| Lundbeck LLC | 15 | $295 |
| AbbVie(2 entities) | 12 | $231 |
| Almatica Pharma LLC | 8 | $201 |
| Biogen | 11 | $195 |
| EMD Serono, Inc. | 12 | $192 |
| Neurelis, Inc. | 10 | $150 |
| Adamas Pharmaceuticals, Inc. | 7 | $96 |
| Eisai Inc. | 3 | $86 |
| Supernus Pharmaceuticals, Inc. | 3 | $72 |
| Upsher-smith Laboratories LLC | 3 | $63 |
| MDD US Operations, LLC | 3 | $61 |
| Acadia Pharmaceuticals Inc | 3 | $45 |
| Assertio Therapeutics, Inc. | 2 | $41 |
| Amgen | 3 | $41 |
| Bausch Health US, LLC | 2 | $40 |
| Avion Pharmaceuticals | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Kvk-tech, Inc. | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| SK Life Science, Inc. | 1 | $24 |
| Vertical Pharmaceuticals, LLC | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Banner Life Sciences, LLC | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Tanabe Pharma America, Inc. | 1 | $12 |
| Kyowa Kirin, Inc. | 1 | $12 |
| Novartis | 1 | $11 |
How this compares
$3,467 in reported general payments places this provider in the 50th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in West Palm Beach
- Paul WinnerWest Palm Beach$624K
- Omer Abdul HamidOrlando$283K
- Natalie GillsonFort Myers$250K
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ronald DavisWinter Park$154K
- Ian MillerMiami$104K
- Michael HammerSaint Petersburg$100K
- Matt LallasMiami$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.